Marcela V. Maus, M.d.,ph.d.
Clinical trials sponsored by Marcela V. Maus, M.d.,ph.d., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on glioblastoma in early trial Results expected Sep 2026 (estimated)
- Double-targeted cell therapy takes on hard-to-treat lymphomas Results expected Jan 2027 (estimated)
-
Could CAR t cells tame vasculitis? early trial aims to find out
Disease control OngoingThis early-phase trial is testing a new treatment called CC-97540, a type of CAR T cell therapy, in 12 people with severe ANCA-associated vasculitis that has not responded to standard treatments. The therapy is designed to target and destroy certain immune cells that drive the di…
Phase 1/2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental CAR t therapy takes on Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial is testing a new type of CAR T cell therapy called TriPRIL for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to better attack cancer,…
Phase 1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC